Xenon Pharmaceuticals Revenue 2012-2022 | XENE
Xenon Pharmaceuticals revenue from 2012 to 2022. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Xenon Pharmaceuticals Annual Revenue
(Millions of US $) |
| 2021 |
$18 |
| 2020 |
$32 |
| 2019 |
$7 |
| 2018 |
$ |
| 2017 |
$0 |
| 2016 |
$2 |
| 2015 |
$16 |
| 2014 |
$28 |
| 2013 |
$27 |
| 2012 |
$14 |
| 2011 |
$7 |
Xenon Pharmaceuticals Quarterly Revenue
(Millions of US $) |
| 2022-09-30 |
$0 |
| 2022-06-30 |
$1 |
| 2022-03-31 |
$9 |
| 2021-12-31 |
$4 |
| 2021-09-30 |
$8 |
| 2021-06-30 |
$2 |
| 2021-03-31 |
$4 |
| 2020-12-31 |
$5 |
| 2020-09-30 |
$7 |
| 2020-06-30 |
$13 |
| 2020-03-31 |
$7 |
| 2019-12-31 |
$3 |
| 2019-09-30 |
$4 |
| 2019-06-30 |
|
| 2019-03-31 |
|
| 2018-12-31 |
|
| 2018-09-30 |
|
| 2018-06-30 |
|
| 2018-03-31 |
|
| 2017-12-31 |
$0 |
| 2017-09-30 |
$0 |
| 2017-06-30 |
$0 |
| 2017-03-31 |
$0 |
| 2016-12-31 |
$0 |
| 2016-09-30 |
$0 |
| 2016-06-30 |
$0 |
| 2016-03-31 |
$1 |
| 2015-12-31 |
$3 |
| 2015-09-30 |
$4 |
| 2015-06-30 |
$4 |
| 2015-03-31 |
$4 |
| 2014-12-31 |
$5 |
| 2014-09-30 |
$13 |
| 2014-06-30 |
$5 |
| 2014-03-31 |
$5 |
| 2013-12-31 |
|
| 2013-09-30 |
$11 |
| 2012-12-31 |
|
| 2011-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$2.451B |
$0.018B |
|
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of medicines through the application of its proprietary discovery platform, which it refer to as Extreme Genetics. Xenon is developing proprietary product candidates for the treatment of both orphan as well as more prevalent diseases. The company offers Glybera (R), a gene therapy for the treatment of lipoprotein lipase deficiency, an orphan disorder. Xenon Pharmaceuticals Inc. is headquartered in Burnaby, Canada.
|
